secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001628280-26-001189
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical reports record Q4 sales $823M (+25% YoY); FY2026 guidance $3.18-3.22B
--------------------------------------------------------------------------------

- Preliminary Q4 2025 sales ~$823.2M, +25.2% YoY; full year sales ~$2.936B, +16.5% YoY.
- Base business (ex-Nevro) Q4 revenue $723.3M, +10.0% YoY, led by US Spine.
- Enabling Technologies delivered best quarterly revenue performance to date.
- FY2026 revenue guidance $3.18B-$3.22B; non-GAAP EPS guidance $4.30-$4.40.
- Final Q4/FY2025 results expected on February 24, 2026 after market close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000162828026001189/0001628280-26-001189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000162828026001189/gmed-20260107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-001189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer